Replies to post #208190 on Biotech Values

[gfp927z]

Traderbx, >> Teva <<



Dew is the expert to ask, but in retrospect I think the company's main problem was having such a large part of their revenue stream from one drug, Copaxone. Additionally, since Teva is the 800 lb gorilla of generic drugs, any possible reimbursement issues for the generic sector as a whole have a larger effect.